MAP2K1 and neoplasm: These treatment-induced MEK1 mutations include those detected not only in primary cancers (F53L, C121S, and E203K) but also in RASopathies (P124Q and P124L), suggesting that any of the disease-associated MEK1 mutants can confer resistance to ERK pathway-targeted therapeutics on tumor cells.